Loading...
NPI 1194906172 · Edison, NJ · Long Term Care Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Pharmcare Usa Of Edison, Inc. is a long term care pharmacy provider located in Edison, New Jersey. This profile covers 9 Medicare and 11 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Pharmcare Usa Of Edison, Inc. |
| Address | 450 Raritan Center Pkwy Ste C |
| City | Edison |
| State | NJ |
| ZIP | 08837 |
| Taxonomy | Long Term Care Pharmacy |
| NPI Enumerated | November 19, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $299.7K |
| Medicaid | $820 |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 400 | $280 | $114K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 930 | $80 | $70.8K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 320 | $140 | $46.2K |
| G0008 | Administration of influenza virus vaccine | 940 | $30 | $31.9K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 320 | $50 | $14.5K |
| G0009 | Administration of pneumococcal vaccine | 430 | $30 | $14.4K |
| 0124A | N/A | 90 | $40 | $4.1K |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 20 | $130 | $2.8K |
| 0134A | N/A | 30 | $40 | $1.2K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 9 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 10 | $20 | $290 |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 150 | $1 | $150 |
| 0004A | N/A | 50 | $1 | $140 |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 10 | $10 | $80 |
| 0003A | N/A | 40 | $1 | $70 |
| 0054A | N/A | 40 | $0 | $0 |
| 0124A | N/A | 50 | $0 | $0 |
| 0134A | N/A | 10 | $0 | $0 |
| 90653 | This code represents an inactivated influenza vaccine product that contains subunits of the virus and an adjuvant to enhance the immune response. The vaccine is administered via separately reportable… | 30 | $0 | $0 |
| 90682 | This code represents a quadrivalent flu vaccine given by injection into the muscle. The vaccine is made using recombinant DNA technology and contains only a protein from the virus. It does not… | 20 | $0 | $0 |
Showing 1–10 of 11
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
11 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90682 | This code represents a quadrivalent flu vaccine given by injection into the muscle. The vaccine is made using recombinant DNA technology and contains only a protein from the virus. It does not… | 127 | 150 | 40 | $30 | $5.5K |
| 0004A | N/A | 46 | 100 | 40 | $30 | $3K |
| 0003A | N/A | 24 | 70 | 20 | $20 | $2.3K |
| 0134A | N/A | 30 | 30 | 50 | $20 | $1.3K |
| 0054A | N/A | 20 | 50 | 40 | $10 | $1.2K |
| 0124A | N/A | 25 | 70 | 30 | $10 | $1.1K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 78 | 90 | 30 | $10 | $820 |
| G0008 | Administration of influenza virus vaccine | 134 | 870 | 50 | $1 | $550 |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 15 | 130 | 40 | $10 | $500 |
| 90653 | This code represents an inactivated influenza vaccine product that contains subunits of the virus and an adjuvant to enhance the immune response. The vaccine is administered via separately reportable… | 33 | 80 | 20 | $10 | $370 |
Showing 1–10 of 11
Other providers in the same ZIP code as Pharmcare Usa Of Edison, Inc., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.